Cargando...
IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
OBJECTIVE: Approximately 10%–20% of patients with familial Mediterranean fever (FMF) show an inadequate response to colchicine. In our cohort study, patients with FMF with or without amyloidosis and with an inadequate response to colchicine were treated with anakinra or canakinumab. METHODS: Clinica...
Guardado en:
| Publicado en: | Eur J Rheumatol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Medical Research and Education Association
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6267760/ https://ncbi.nlm.nih.gov/pubmed/30501849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/eurjrheum.2018.18036 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|